Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|June 4, 2026

The BioPharm Brief: Breakthroughs, Bispecifics, and Biosimilars

Today's biopharmaceutical news highlights an FDA breakthrough designation in spinal muscular atrophy, an expanded oncology collaboration focused on tumor activated bispecifics, and a new biosimilar launch for retinal diseases in Europe.


Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today’s update covers three stories spanning rare disease, oncology, and biosimilars, each highlighting how companies are advancing new treatment options and expanding access to established therapies.

First, Biogen announced that its investigational antisense oligonucleotide salanersen has received FDA Breakthrough Therapy Designation for spinal muscular atrophy, or SMA. The designation was supported by Phase 1b data showing improvements in motor function and reductions in neurofilament levels, a marker associated with neurodegeneration, in some children who had previously received gene therapy. Salanersen is designed as a once yearly treatment and is now advancing through a global Phase 3 clinical program. The designation could help accelerate development and regulatory interactions as Biogen continues evaluating the therapy's potential role in SMA treatment.

Next, CytomX Therapeutics and Regeneron are expanding their collaboration to develop tumor activated bispecific cancer therapies. The companies are leveraging CytomX’s masking technology, which is designed to keep therapies inactive until they reach the tumor microenvironment. The goal is to improve precision while potentially reducing off target effects. The expanded agreement reflects continued industry interest in next generation immuno oncology approaches that may widen the therapeutic window for cancer treatments.

Finally, Teva has launched Ahzantive, an aflibercept biosimilar referencing Eylea, in Europe. The product is indicated for several retinal diseases and expands Teva’s biosimilars portfolio in a major ophthalmology market. As biosimilar competition continues to grow, new entrants such as Ahzantive may help improve patient access while supporting healthcare system sustainability.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • Biogen's salanersen received FDA Breakthrough Therapy Designation based on encouraging early SMA data.
  • CytomX and Regeneron are advancing tumor activated bispecific therapies designed to improve cancer treatment precision.
  • Teva expanded its European biosimilars portfolio with the launch of the aflibercept biosimilar Ahzantive.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more